ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BTG Btg Plc

840.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Btg Plc LSE:BTG London Ordinary Share GB0001001592 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 840.00 839.00 840.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

BTG PLC Varithena® Receives Finalised Category I CPT Codes (5907V)

06/11/2017 7:00am

UK Regulatory


Btg (LSE:BTG)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Btg Charts.

TIDMBTG

RNS Number : 5907V

BTG PLC

06 November 2017

BTG plc: Varithena(R) receives finalised category I CPT codes

New payment rates and automatic electronic processing of claims effective 1 January 2018

London, UK, 6 November 2017: BTG plc (LSE: BTG), the global specialist healthcare company, notes that the US Centers for Medicare and Medicaid Services have published the final fee schedule for new Category I CPT codes for Varithena(R) procedures. The codes will be effective from 1 January 2018.

The fee schedule details payments for conducting Varithena(R) treatments in the physician office setting of $1,624.30 for a single vein and $1,697.02 for multiple veins. The new CPT codes define Medicare payment rates and enable automatic and electronic processing of claims, providing physicians in the US with further predictability of payment and streamlining the reimbursement process.

"We believe the new CPT codes are appropriate and have the potential to underpin our current expectations for the product," commented Louise Makin, BTG's CEO. "However, we must wait and see how they impact physician adoption and insurer practices, and we should have a better understanding of that by the end of 2018."

For further information contact

BTG

Andy Burrows, VP Corporate & Investor Relations

+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605

Stuart Hunt, Investor Relations Manager

+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536

Chris Sampson, Corporate Communications Director

+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178

FTI Consulting

Ben Atwell/Simon Conway

+44 (0)20 3727 1000

About BTG

BTG is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: btgplc.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCDMMGMGKRGNZZ

(END) Dow Jones Newswires

November 06, 2017 02:00 ET (07:00 GMT)

1 Year Btg Chart

1 Year Btg Chart

1 Month Btg Chart

1 Month Btg Chart

Your Recent History

Delayed Upgrade Clock